Items tagged with Drug-susceptible TB
The World Health Organization (WHO) is convening a Guideline Development Group (GDG) to advise on updates needed to its recommendations on the treatment of drug susceptible tuberculosis (TB).
14 June 2021, Geneva | A rapid communication released by the World Health Organization (WHO) Global Tuberculosis Programme announced updates to the current treatment regimen for people with TB. A review of evidence by WHO has shown similar performance of a shorter treatment regimen compared to the current standard regimen, both in terms of efficacy and safety. The 4-month regimen, which is shorter, effective and all-oral, would be a preference for many patients and also national TB programmes, allowing faster cure and easing the burden on both patients and the healthcare system. Shortened treatment has the potential to improve adherence and reduce patient and health system costs.
Point-of-care diagnostics for tuberculosis elimination? (post with simple image)
The projected epidemiological effect of Xpert MTB/RIF might be overestimated, so this fascinating and promising new tool is unlikely to be the magic bullet that paves the way towards tuberculosis elimination.
New tuberculosis drug regimen will move to landmark Phase 3 clinical trial (post with simple image)
STAND trial will test the first regimen designed to significantly shorten and simplify the treatment of drug-sensitive and drug-resistant TB.
The use of bedaquiline in regimens to treat drug-resistant and drug-susceptible tuberculosis: a perspective from tuberculosis-affected communities (post with simple image)
Community voices on bedaquiline's use to treat drug-resistant tuberculosis and future development as a potential treatment for drug-susceptible disease have been largely unheard.
Attempt to shorten standard tuberculosis treatment fails in REMoxTB trial (post with simple image)
Two 4-month treatment regimens containing moxifloxacin are less effective than the standard 6-month regimen for drug-sensitive tuberculosis.
Global Phase 3 “STAND” trial launched to test new tuberculosis drug regimen PaMZ to shorten, improve treatment (post with simple image)
STAND trial will take place in approximately 50 study sites in Africa, Asia, Caribbean, Eastern Europe, and Latin America; Results published in The Lancet show PaMZ’s promise to dramatically shorten and simplify therapy for patients with drug-resistant TB; Regimen could improve treatment for those with drug-sensitive TB and those with HIV co-infection.
The Lancet: Results of Phase 2b trial of novel TB regimen PaMZ show potential to shorten, improve TB treatment (post with simple image)
Phase 3 STAND trial launched to advance PaMZ through final stage of testing.
Treating drug-sensitive TB in India: Implementation of daily therapy with fixed-dose combinations (post with simple image)
A briefing document outlines critical steps needed to implement a new policy from the Indian government to switch to standard daily TB treatment using fixed-dose combinations. This change, which is in line with global recommendations for proper treatment, is welcome but has yet to be put into action.
Tuberculosis in adults and children (post with simple image)
A monograph written for healthcare workers in any setting who are faced with the complex care for patients with tuberculosis.
Page 2 of 3 · Total posts: 0←First 1 2 3 Last→